The following 24 -page report from Judicial Watch documents 18 deaths that have occurred following vaccination with GARDASIL. Eleven of these deaths occurred within one week of receiving the vaccine.
http://www.judicialwatch.org/documents/2008/JWReportFDAhpvVaccineRecords.pdf
Finally, in a CBS news report by Sharyl Attkisson on GARDASIL, Merck and the CDC are quoted stating that GARDASIL “Appears safer than most vaccines” and has “Half the average reported serious adverse events.”
If this statement were really true, what does that say about the safety of the other vaccines?
As of July 2017 there have been 41.827 adverse events following the Gardasil vaccine reported to VAERS, including 5.533 serious adverse events and 266 deaths.
GARDASIL – Merck – Product Insert
http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf
GARDASIL® is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine:
And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, and 18:
GARDASIL is indicated in boys and men 9 through 26 years of age for the prevention of the following diseases caused by HPV types included in the vaccine:
And the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18:
GARDASIL has not been demonstrated to protect against diseases due to HPV types not contained in the vaccine. (Page 2)
Overall Summary of Adverse Reactions: Headache, fever, nausea, and dizziness; and local injection site reactions (pain, swelling, erythema, pruritus, and bruising) occurred after administration with GARDASIL. (Page 3)
Syncope, sometimes associated with tonic-clonic movements and other seizure-like activity, has been reported following vaccination with GARDASIL. Because vaccinees may develop syncope, sometimes resulting in falling with injury; observation for 15 minutes after administration is recommended. (Page 3)
Anaphylaxis has been reported following vaccination with GARDASIL. (Page 4)
In the clinical safety studies a saline placebo was actually used. However, the three groups of subjects were broken down as follows: 15,706 received GARDASIL, 13,023 received AAHS control, and 594 received the saline placebo. (p.7)
AAHS is Amorphous Aluminum Hydroxyphosphate Sulfate. Therefore 28,729 subjects received an active substance and 594 received the placebo. The greater problem is that except for injection site reacations, they did not compare the three groups separately, but compared the GARDASIL group to the AAHS group and the placebo together.
Furthermore, AAHS is the adjuvant (the portion of the vaccine that triggers the immune response) in GARDASIL, so the clinical studies were merely comparing GARDASIL to a toxic portion of itself.
Serious adverse events in this study that were judged by the study investigator to be vaccine related included headache, gastroenteritis, appendicitis, pelvic inflammatory disease, urinary tract infection, pneumonia, pyelonephritis, pulmonary embolism, bronchospasm and asthma.
Clinical studies also found in 2.3% of girls and women who received Gardasil reported an incident condition potentially indicative of a systemic autoimmune disorder after enrolling in the study. These disorders included arthralgia/arthritis/arthropathy, autoimmune thyroiditis, celiac disease, insulin dependent diabetes mellitus, erythema nodosum, hyperthyroidism, hypothyroidism, inflammatory bowel disease, multiple sclerosis, nephritis, optic neuritis, pigmenation disorder, psoriasis, Raynaud's Phenomenon, rheumatoid arthritis, schleroderma/morphea, Steven-Johnson Syndrome, Systemic Lupus Erythematosus, and uveitis. (Page 8)
Clinical studies also found in 1.5% of boys and men who received Gardasil reported an incident condition potentially indicative of a systemic autoimmune disorder after enrolling in the study. These disorders included alopecia areata, ankylosing spondylitis, arthralgia/arthritis/reactive arthritis, autoimmune thrombocytopenia, diabetes mellitus type 1, hyperthyroidism, hypethyroidism, inflammatory bowel disease, myocarditis, proteinuria, psoriasis, skin depigmentation and vitiligo (Page 9)
“GARDASIL has not been evaluated for the potential to cause carcinogenicity or genotoxicity.” (Page 12)
GARDASIL Ingredients: yeast protein, vitamins, amino acids, mineral salts, carbohydrates, amorphous aluminum hydroxyphosphate sulfate, sodium chloride, L-histidine, polysorbate 80, sodium borate
http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf